Armata Pharmaceuticals Net Income
| ARMP Stock | USD 8.10 0.35 4.52% |
As of the 5th of February, Armata Pharmaceuticals shows the Risk Adjusted Performance of 0.1106, downside deviation of 6.61, and Mean Deviation of 5.3. Armata Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Armata Pharmaceuticals Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 148.1376 | Revenue | Earnings Share (1.66) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -17 M | -17.9 M | |
| Net Loss | -33.2 M | -34.9 M | |
| Net Loss | -17 M | -17.9 M | |
| Net Loss | (0.47) | (0.49) | |
| Net Income Per E B T | 0.83 | 0.96 |
Armata | Net Income | Build AI portfolio with Armata Stock |
Evaluating Armata Pharmaceuticals's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Armata Pharmaceuticals's fundamental strength.
Latest Armata Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Armata Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Armata Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Armata Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Armata Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Armata Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (18.92 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Armata Net Income Regression Statistics
| Arithmetic Mean | (18,845,236) | |
| Geometric Mean | 12,850,205 | |
| Coefficient Of Variation | (117.77) | |
| Mean Deviation | 14,395,217 | |
| Median | (17,875,620) | |
| Standard Deviation | 22,193,201 | |
| Sample Variance | 492.5T | |
| Range | 92.2M | |
| R-Value | (0.36) | |
| Mean Square Error | 457.3T | |
| R-Squared | 0.13 | |
| Significance | 0.16 | |
| Slope | (1,581,715) | |
| Total Sum of Squares | 7880.6T |
Armata Net Income History
Other Fundumenentals of Armata Pharmaceuticals
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Armata Pharmaceuticals Net Income component correlations
Armata Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Armata Pharmaceuticals is extremely important. It helps to project a fair market value of Armata Stock properly, considering its historical fundamentals such as Net Income. Since Armata Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Armata Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Armata Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does Armata have expansion opportunities? Factors like these will boost the valuation of Armata Pharmaceuticals. If investors know Armata will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Armata Pharmaceuticals demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (1.66) | Revenue Per Share | Quarterly Revenue Growth (0.61) | Return On Assets | Return On Equity |
Armata Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Armata's balance sheet. Smart investors calculate Armata Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Armata Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Armata Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Armata Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Armata Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Armata Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Armata Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Armata Pharmaceuticals.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Armata Pharmaceuticals on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Armata Pharmaceuticals or generate 0.0% return on investment in Armata Pharmaceuticals over 90 days. Armata Pharmaceuticals is related to or competes with GeoVax Labs, BioLineRx, Tharimmune, Apollomics, Ainos, OSR Holdings, and Lipocine. Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriopha... More
Armata Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Armata Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Armata Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 6.61 | |||
| Information Ratio | 0.1292 | |||
| Maximum Drawdown | 38.51 | |||
| Value At Risk | (8.33) | |||
| Potential Upside | 14.73 |
Armata Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Armata Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Armata Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Armata Pharmaceuticals historical prices to predict the future Armata Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.1106 | |||
| Jensen Alpha | 0.8857 | |||
| Total Risk Alpha | 0.4548 | |||
| Sortino Ratio | 0.142 | |||
| Treynor Ratio | 0.5037 |
Armata Pharmaceuticals February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1106 | |||
| Market Risk Adjusted Performance | 0.5137 | |||
| Mean Deviation | 5.3 | |||
| Semi Deviation | 5.83 | |||
| Downside Deviation | 6.61 | |||
| Coefficient Of Variation | 724.2 | |||
| Standard Deviation | 7.27 | |||
| Variance | 52.79 | |||
| Information Ratio | 0.1292 | |||
| Jensen Alpha | 0.8857 | |||
| Total Risk Alpha | 0.4548 | |||
| Sortino Ratio | 0.142 | |||
| Treynor Ratio | 0.5037 | |||
| Maximum Drawdown | 38.51 | |||
| Value At Risk | (8.33) | |||
| Potential Upside | 14.73 | |||
| Downside Variance | 43.68 | |||
| Semi Variance | 33.96 | |||
| Expected Short fall | (5.78) | |||
| Skewness | 0.1899 | |||
| Kurtosis | 0.9562 |
Armata Pharmaceuticals Backtested Returns
Armata Pharmaceuticals appears to be moderately volatile, given 3 months investment horizon. Armata Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.11, which signifies that the company had a 0.11 % return per unit of risk over the last 3 months. By analyzing Armata Pharmaceuticals' technical indicators, you can evaluate if the expected return of 0.83% is justified by implied risk. Please makes use of Armata Pharmaceuticals' Risk Adjusted Performance of 0.1106, mean deviation of 5.3, and Downside Deviation of 6.61 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Armata Pharmaceuticals holds a performance score of 8. The firm shows a Beta (market volatility) of 1.97, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Armata Pharmaceuticals will likely underperform. Please check Armata Pharmaceuticals' downside variance, and the relationship between the sortino ratio and accumulation distribution , to make a quick decision on whether Armata Pharmaceuticals' price patterns will revert.
Auto-correlation | -0.09 |
Very weak reverse predictability
Armata Pharmaceuticals has very weak reverse predictability. Overlapping area represents the amount of predictability between Armata Pharmaceuticals time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Armata Pharmaceuticals price movement. The serial correlation of -0.09 indicates that less than 9.0% of current Armata Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.09 | |
| Spearman Rank Test | 0.04 | |
| Residual Average | 0.0 | |
| Price Variance | 0.35 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Armata Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Armata Pharmaceuticals reported net income of (18.92 Million). This is 105.54% lower than that of the Biotechnology sector and 127.01% lower than that of the Health Care industry. The net income for all United States stocks is 103.31% higher than that of the company.
Armata Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Armata Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Armata Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Armata Pharmaceuticals by comparing valuation metrics of similar companies.Armata Pharmaceuticals is currently under evaluation in net income category among its peers.
Armata Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Armata Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Armata Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Armata Fundamentals
| Return On Equity | -34.39 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (6.71) % | ||||
| Current Valuation | 444.72 M | ||||
| Shares Outstanding | 36.41 M | ||||
| Shares Owned By Insiders | 69.12 % | ||||
| Shares Owned By Institutions | 2.27 % | ||||
| Number Of Shares Shorted | 222.05 K | ||||
| Price To Earning | (1.65) X | ||||
| Price To Book | 2.11 X | ||||
| Price To Sales | 55.83 X | ||||
| Revenue | 5.17 M | ||||
| Gross Profit | (21.04 M) | ||||
| EBITDA | (41.11 M) | ||||
| Net Income | (18.92 M) | ||||
| Cash And Equivalents | 36.98 M | ||||
| Cash Per Share | 1.02 X | ||||
| Total Debt | 126.52 M | ||||
| Debt To Equity | 0.73 % | ||||
| Current Ratio | 5.59 X | ||||
| Book Value Per Share | (2.64) X | ||||
| Cash Flow From Operations | (37.55 M) | ||||
| Short Ratio | 4.49 X | ||||
| Earnings Per Share | (1.66) X | ||||
| Target Price | 12.0 | ||||
| Number Of Employees | 60 | ||||
| Beta | 1.42 | ||||
| Market Capitalization | 282.15 M | ||||
| Total Asset | 86.44 M | ||||
| Retained Earnings | (327.74 M) | ||||
| Working Capital | (36.94 M) | ||||
| Current Asset | 4.48 M | ||||
| Current Liabilities | 4.08 M | ||||
| Net Asset | 86.44 M |
About Armata Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Armata Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Armata Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Armata Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Armata Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Armata Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Armata Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Armata Stock
| 0.58 | QSI | QuantumSi | PairCorr |
| 0.52 | LYRA | Lyra Therapeutics | PairCorr |
| 0.44 | EDIT | Editas Medicine | PairCorr |
| 0.42 | GNLX | Genelux Common | PairCorr |
| 0.39 | KRRO | Frequency Therapeutics | PairCorr |
The ability to find closely correlated positions to Armata Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Armata Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Armata Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Armata Pharmaceuticals to buy it.
The correlation of Armata Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Armata Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Armata Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Armata Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Armata Stock Analysis
When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.